Suppr超能文献

可变环聚糖依赖性广谱高效 HIV-1 中和抗体 PG9 和 PG16。

Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.

机构信息

Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA.

出版信息

J Virol. 2010 Oct;84(20):10510-21. doi: 10.1128/JVI.00552-10. Epub 2010 Aug 4.

Abstract

The HIV-1-specific antibodies PG9 and PG16 show marked cross-isolate neutralization breadth and potency. Antibody neutralization has been shown to be dependent on the presence of N-linked glycosylation at position 160 in gp120. We show here that (i) the loss of several key glycosylation sites in the V1, V2, and V3 loops; (ii) the generation of pseudoviruses in the presence of various glycosidase inhibitors; and (iii) the growth of pseudoviruses in a mutant cell line (GnT1(-/-)) that alters envelope glycosylation patterns all have significant effects on the sensitivity of virus to neutralization by PG9 and PG16. However, the interaction of antibody is not inhibited by sugar monosaccharides corresponding to those found in glycans on the HIV surface. We show that some of the glycosylation effects described are isolate dependent and others are universal and can be used as diagnostic for the presence of PG9 and PG16-like antibodies in the sera of HIV-1-infected patients. The results suggest that PG9 and PG16 recognize a conformational epitope that is dependent on glycosylation at specific variable loop N-linked sites. This information may be valuable for the design of immunogens to elicit PG9 and PG16-like antibodies, as well as constructs for cocrystallization studies.

摘要

HIV-1 特异性抗体 PG9 和 PG16 表现出明显的交叉分离中和广度和效力。抗体中和作用已被证明依赖于 gp120 位置 160 处 N 连接糖基化的存在。我们在这里表明:(i)V1、V2 和 V3 环中几个关键糖基化位点的缺失;(ii)在存在各种糖苷酶抑制剂的情况下产生假病毒;以及(iii)在改变包膜糖基化模式的突变细胞系(GnT1(-/-))中生长的假病毒,所有这些都对 PG9 和 PG16 中和病毒的敏感性有显著影响。然而,抗体的相互作用不受对应于 HIV 表面糖蛋白上糖链的糖单糖抑制。我们表明,描述的一些糖基化效应是分离依赖性的,而另一些是普遍的,可以用作 HIV-1 感染患者血清中存在 PG9 和 PG16 样抗体的诊断。结果表明,PG9 和 PG16 识别依赖于特定可变环 N 连接糖基化位点的构象表位。这些信息对于设计免疫原以引发 PG9 和 PG16 样抗体以及用于共结晶研究的构建体可能是有价值的。

相似文献

1
Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.
J Virol. 2010 Oct;84(20):10510-21. doi: 10.1128/JVI.00552-10. Epub 2010 Aug 4.
2
Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.
Nat Struct Mol Biol. 2013 Jul;20(7):804-13. doi: 10.1038/nsmb.2600. Epub 2013 May 26.
5
6
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.
Nature. 2011 Nov 23;480(7377):336-43. doi: 10.1038/nature10696.
7
Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies.
J Virol. 2011 May;85(9):4578-85. doi: 10.1128/JVI.02585-10. Epub 2011 Feb 16.
9
V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1.
J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):237-45. doi: 10.1097/QAI.0000000000000854.

引用本文的文献

2
Immunization of cows with HIV envelope trimers generates broadly neutralizing antibodies to the V2-apex from the ultralong CDRH3 repertoire.
PLoS Pathog. 2024 Sep 9;20(9):e1012042. doi: 10.1371/journal.ppat.1012042. eCollection 2024 Sep.
4
Characterization and application of recombinant Bovine Leukemia Virus Env protein.
Sci Rep. 2024 May 28;14(1):12190. doi: 10.1038/s41598-024-62811-8.
5
Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives.
Clin Microbiol Rev. 2024 Jun 13;37(2):e0015222. doi: 10.1128/cmr.00152-22. Epub 2024 Apr 30.
6
HIV envelope trimers and gp120 as immunogens to induce broadly neutralizing antibodies in cows.
bioRxiv. 2024 Mar 25:2024.03.20.585065. doi: 10.1101/2024.03.20.585065.
7
Potent antibody-dependent cellular cytotoxicity of a V2-specific antibody is not sufficient for protection of macaques against SIV challenge.
PLoS Pathog. 2024 Jan 22;20(1):e1011819. doi: 10.1371/journal.ppat.1011819. eCollection 2024 Jan.
8
Influence of glycosylation on the immunogenicity and antigenicity of viral immunogens.
Biotechnol Adv. 2024 Jan-Feb;70:108283. doi: 10.1016/j.biotechadv.2023.108283. Epub 2023 Nov 14.
10
Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization.
PLoS Pathog. 2023 Oct 30;19(10):e1011601. doi: 10.1371/journal.ppat.1011601. eCollection 2023 Oct.

本文引用的文献

2
Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.
Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13800-5. doi: 10.1073/pnas.1006498107. Epub 2010 Jul 19.
3
Immunology and the elusive AIDS vaccine.
Nature. 2010 Mar 11;464(7286):224-31. doi: 10.1038/nature08898.
4
The role of antibodies in HIV vaccines.
Annu Rev Immunol. 2010;28:413-44. doi: 10.1146/annurev-immunol-030409-101256.
5
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.
Science. 2009 Oct 9;326(5950):285-9. doi: 10.1126/science.1178746. Epub 2009 Sep 3.
6
Glycosylation site-specific analysis of clade C HIV-1 envelope proteins.
J Proteome Res. 2009 Sep;8(9):4231-42. doi: 10.1021/pr9002728.
7
Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays.
Curr Protoc Immunol. 2005 Jan;Chapter 12:12.11.1-12.11.17. doi: 10.1002/0471142735.im1211s64.
9
Distinct roles for DC-SIGN+-dendritic cells and Langerhans cells in HIV-1 transmission.
Trends Mol Med. 2008 Jan;14(1):12-9. doi: 10.1016/j.molmed.2007.11.001. Epub 2007 Dec 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验